Telix Assets

About: Telix is developing 89Zr-TX250 for the diagnosis of clear cell renal cell carcinoma (ccRcc) and 177Lu-TX250 for the treatment of metastatic ccRcc.

Mechanism of Action: The TX250 antibody binds carbonic anhydrase 9 (CAIX). CAIX is highly expressed by ccRcc tumours, including metastases.

Importance in ccRcc diagnosis: There is a significant unmet need for better diagnostic methods for preoperative characterisation and staging of ccRcc.

 

Asset_1

About:177Lu-TX591 is derived from the huJ591 humanised mAb, originally developed by Neil Bander at Weill Cornell Medical College.

Mechanism of Action: TX591 targets Prostate Specific Membrane Antigen (PSMA), which is over-expressed in prostate cancer.

Need for novel treatments in prostate cancer: Late-stage/end-stage metastatic prostate cancer patients have very few treatment options beyond chemotherapy. Despite initial therapy, about 30% of men suffer from relapse suggesting that there is a need for further treatment options in patients with high-grade disease.

 

Asset_2

About: Telix is developing 124I-TX101 for imaging (diagnosis, staging and treatment response) and 131I-TX101 for therapy of glioblastoma multiforme (GBM).

Mechanism of Action: TX101 targets LAT-1 (L-type amino acid transporter), which is over expressed in many gliomas. The mechanism of action of TX101 not only delivers potent targeted radiation but it also increases the efficacy of external beam radiation, used as standard of care in GBM treatment.

Need for treatment options: GBM is one of the most challenging brain tumours to treat. It is an aggressive disease and median survival is usually less than 18 months after diagnosis. Standard of care is surgical resection of the tumour, followed by radiotherapy and temozolomide (TMZ) treatment.

 

Asset_3